Whether a trial enrolls a population that reflects the people who live with the disease is largely decided before recruitment begins. Eligibility criteria, visit burden, site locations, investigator networks, participant support budgets and language access all shape who can realistically take part. Representative enrollment is an operational design problem, and it is best solved at the design stage.
Why does it start with the protocol?
Exclusion criteria built around common comorbidities, narrow laboratory thresholds or age limits can disproportionately exclude groups more affected by the disease. Frequent, long visits and procedures that require travel to specialized centers create burdens that fall unevenly on people with less flexible jobs, caregiving responsibilities or long distances to travel. Each criterion and procedure deserves the question: is this scientifically necessary, and who does it keep out?
Where are your sites?
Site selection based mostly on past enrollment performance tends to favor large academic centers. Those centers matter, but many patients receive care in community settings closer to home. Including community sites and investigators who already have trusted relationships with underrepresented patients can change who enrolls.
What does participant support cost?
Travel reimbursement, parking, meals, childcare, flexible visit hours, home or remote visits where appropriate, and translated materials and interpreters. These are not extras. They determine whether participation is possible. Budget them up front, rather than hoping to find money once enrollment patterns become a concern.
How do you set goals and measure progress?
Use the epidemiology of the disease to define what representative enrollment would look like for your study. Track enrollment demographics by site as the study proceeds, and act early if patterns diverge from the goal. Waiting until the end of enrollment leaves nothing to adjust.
What role does community engagement play?
A central one. Patient advocacy groups, community health organizations and trusted local leaders can help shape protocols, materials and outreach. Trust is built over time, ideally long before a study needs participants, and it is earned by listening, not just by asking.
Why does it matter?
Scientifically, results from a narrow population may not generalize. Regulators, payers and clinicians increasingly want evidence that reflects the patients who will actually use a medicine. And ethically, the benefits and burdens of research should be shared fairly. For an emerging sponsor, getting this right early also builds a reputation that pays off in every future study.
Where should a sponsor start?
At the next protocol review. Ask which eligibility criteria and procedures could be simplified without compromising safety or the science, and where sites could be added to reach patients closer to home. Small design choices made early often matter more than large recruitment campaigns launched late.
Keep reading: Enrollment Contingency Planning Before You Need It
